Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients

Journal of Clinical Pathology

Volumn 63, Issue 8, 2010, Pages 678-680

  Arnold, D F ^a   Timms, A ^a   Luqmani, R ^b   Misbah, S A ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEUTROPHIL CYTOPLASM ANTIBODY; BIOLOGICAL MARKER; UNCLASSIFIED DRUG;

ANTIBODY SCREENING; ARTICLE; DELAYED DIAGNOSIS; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MICROSCOPIC POLYANGIITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; HUMANS; IMMUNOASSAY; MEDICAL AUDIT; PATIENT SELECTION; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 77955723479     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.072504     Document Type: Article

References (9)

1. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997;337:1512-23.
2. van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985;1:425-9. (Pubitemid 15173133)
3. Andrews M, Edmunds M, Campbell A, et al. Systemic vasculitis in the 1980s - is there an increasing incidence of Wegener's granulomatosis and microscopic polyarteritis? J R Coll Physicians Lond 1990;24:284-8.
4. McLaren JS, Stimson RH, McRorie ER, et al. The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting. Qjm 2001;94:615-21.
5. Sinclair D, Saas M, Stevens JM. The effect of a symptom related 'gating policy' on ANCA requests in routine clinical practice. J Clin Pathol 2004;57:131-4.
6. Jarius S, Eichhorn P, Albert MH, et al. Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFalpha-dependent and Fc-receptor-independent way. Blood 2007;109:4376-82. (Pubitemid 46743406)
7. Jolles S, Deacock S, Turnbull W, et al. Atypical C-ANCA following high dose intravenous immunoglobulin. J Clin Pathol 1999;52:177-80. (Pubitemid 29125408)
8. Savige J, Gillis D, Benson E, et al. International consensus statement on testing and reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 1999;111:507-13. (Pubitemid 29153147)
9. Robinson PC, Steele RH. Appropriateness of antineutrophil cytoplasmic antibody testing in a tertiary hospital. J Clin Pathol 2009;62:743-5.